

Applicants: Jingrong Cao et al.
Application No.: 10/696,862

REMARKS

The Claim Amendments

Claims 1, 21-22, 28-35, 38-39, and 45 have been amended to correct informalities. In particular, a redundant use of the term "wherein" has been deleted from claim 1 and a period has been added to the end of each of claims 21-22, 28-35, 38-39, and 45.

Claims 47-53 have been canceled.

Claim 54 has been rewritten in independent form to recite a method of treating or lessening the severity of a disease or disorder selected from Alzheimer's disease, an allergy, asthma, or diabetes in a patient with a compound or composition of the invention. Support for this amendment is found in paragraphs [00144] to [00146] on page 103 of the specification.

Claims 55-56 have been amended such that they are now dependent upon claim 54.

The Response

Rejection under 35 U.S.C. § 112, first paragraph

The Examiner has maintained the rejection of claims 47-53 under 35 U.S.C. § 112, first paragraph. These claims have been canceled, thereby obviating the rejection.

Rejection under 35 U.S.C. § 101

The Examiner has issued a new rejection of claims 48 and 49 under 35 U.S.C. § 101 for allegedly lacking utility. These claims have been canceled, thereby obviating the rejection.

Applicants: Jingrong Cao et al.
Application No.: 10/696,862

Objection to the Claims

Under the subtitle "Allowable Subject Matter" on page 18 of the Advisory Action, the Examiner has objected to claims 54-56 as being dependent upon a rejected base claims and states that these claims would be allowable if rewritten in independent form. However, applicants note that, in contrast to this statement, the Examiner has indicated that claims 54-56 are withdrawn from consideration on form PTOL-303. Clarification on this matter is requested.

Claims 54-56 have been combined into one claim, claim 54, which has been rewritten in independent form to recite all of the limitations of canceled base claim 50. Claims 55 and 56 have been amended to base their dependencies upon claim 54. Accordingly, applicants request that the Examiner withdraw this objection.

Conclusion

Applicants request that the Examiner enter the above amendments, consider the accompanying arguments, and allow the claims to pass to issue. Should the Examiner deem expedient a telephone discussion to further the prosecution of the above application, applicants request that the Examiner contact the undersigned at his convenience.

Respectfully submitted,



Daniel A. Pearson (Reg. No. 58,053)

Agent for Applicants

c/o Vertex Pharmaceuticals Incorporated

130 Waverly Street

Cambridge, MA 02139-4242

Tel.: (617) 444-6790

Fax.: (617) 444-6483